[1]
Tollefson J. Climate change is hitting the planet faster than scientists originally thought. Nature
[http://dx.doi.org/10.1038/d41586-022-00585-7]
[http://dx.doi.org/10.1038/d41586-022-00585-7]
[2]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052]
[http://dx.doi.org/10.1016/j.cell.2020.02.052]
[3]
Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance 2020; 3(9)e202000786
[http://dx.doi.org/10.26508/lsa.202000786]
[http://dx.doi.org/10.26508/lsa.202000786]
[4]
Papa G, Mallery DL, Albecka A, et al. Furin cleavage of SARS-CoV-2 spike promotes but is not essential for infection and cell-cell fusion. PLoS Pathog 2021; 17(1)e1009246
[http://dx.doi.org/10.1371/journal.ppat.1009246]
[http://dx.doi.org/10.1371/journal.ppat.1009246]
[5]
Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015; 23(8): 468-78.
[http://dx.doi.org/10.1016/j.tim.2015.06.003]
[http://dx.doi.org/10.1016/j.tim.2015.06.003]
[6]
Mantzourani C, Vasilakaki S, Gerogianni VE, Kokotos G. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19. Expert Opin Drug Discov 2022; 17(3): 231-46.
[http://dx.doi.org/10.1080/17460441.2022.2029843]
[http://dx.doi.org/10.1080/17460441.2022.2029843]
[7]
Meng B, Abdullahi A, Ferreira IATM, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 2022; 603(7902): 706-14.
[http://dx.doi.org/10.1038/s41586-022-04474-x]
[http://dx.doi.org/10.1038/s41586-022-04474-x]
[8]
Jocher G, Grass V, Tschirner SK, et al. ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion. EMBO Rep 2022; 23(6)e54305
[http://dx.doi.org/10.15252/embr.202154305]
[http://dx.doi.org/10.15252/embr.202154305]
[9]
Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005; 280(34): 30113-9.
[http://dx.doi.org/10.1074/jbc.M505111200]
[http://dx.doi.org/10.1074/jbc.M505111200]
[10]
Aggarwal A, Akerman A, Milogiannakis V, et al. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. EBioMedicine 2022; 84.
[http://dx.doi.org/10.1016/j.ebiom.2022.104270]
[http://dx.doi.org/10.1016/j.ebiom.2022.104270]
Related Journals
Current Computer-Aided Drug Design
